Table 1 OS and PFS according to mutational profiling

From: Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes

Parameter

Overall survival

Progression-free survival

 

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

 

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

Female vs male

0.784 (0.36–1.708)

0.541

  

1.131 (0.578–2.213)

0.7189

  

R-IPSS

1.728 (1.011–2.955)

0.0455

  

1.51 (0.935–2.44)

0.0921

  

AGE

1.013 (0.973–1.054)

0.5431

  

1.02 (0.983–1.058)

0.3003

  

WBC

1.024 (0.987–1.064)

0.2069

  

1.027 (1.001–1.053)

0.0397

1.042 (1.012–1.073)

0.0062

KAR good vs poor

0.588 (0.266–1.301)

0.1901

  

0.603 (0.289–1.258)

0.1778

  

KAR intermediate vs poor

0.831 (0.276–2.499)

0.7415

  

0.815 (0.323–2.057)

0.6644

  

CR/PR/HI VS SD/PD

0.373 (0.175–0.796)

0.0108

0.344 (0.159–0.745)

0.0068

0.315 (0.158–0.628)

0.001

0.264 (0.129–0.541)

0.0003

HSCT

0.399 (0.177–0.900)

0.0267

  

0.473 (0.181–1.231)

0.1249

  

ASXL1 WT VS MUT

0.715 (0.348–1.472)

0.3628

  

0.89 (0.465–1.704)

0.7254

  

CEBPA WT VS MUT

4.155 (0.565–30.546)

0.1618

  

2.194 (0.527–9.133)

0.2802

  

CSF3R WT VS MUT

1.051 (0.367–3.01)

0.9256

  

0.838 (0.35–2.009)

0.692

  

DNMT3A WT VS MUT

0.774 (0.334–1.798)

0.5519

  

0.53 (0.257–1.092)

0.085

  

DNMT3A-R882 WT VS MUT

0.374 (0.125–1.121)

0.0790

  

0.339 (0.137–0.836)

0.0188

  

ETV6 WT VS MUT

0.636 (0.191–2.11)

0.4591

  

0.704 (0.249–1.993)

0.5084

  

EZH2 WT VS MUT

2.615 (0.356–19.223)

0.3448

  

0.923 (0.283–3.01)

0.8943

  

FLT3 WT VS MUT

1.116 (0.338–3.681)

0.8568

  

1.222 (0.375–3.979)

0.7398

  

IDH2 WT VS MUT

0.433 (0.151–1.247)

0.1209

  

0.496 (0.206–1.195)

0.1179

  

KRAS WT VS MUT

0.625 (0.189–2.067)

0.4411

  

0.862 (0.264–2.812)

0.8059

  

NRAS WT VS MUT

4.155 (0.563–30.638)

0.1624

  

1.577 (0.482–5.154)

0.4511

  

PTPN11 WT VS MUT

0.647 (0.225–1.859)

0.4185

  

0.682 (0.265–1.756)

0.4279

  

RUNX1 WT VS MUT

0.783 (0.358–1.709)

0.5388

  

0.919 (0.454–1.862)

0.8148

  

SETBP1 WT VS MUT

0.424 (0.201–0.893)

0.0239

0.420 (0.197–0.893)

0.0241

0.526 (0.268–1.031)

0.0612

  

SETBP1 SKI DOMAIN WT VS MUT

0.548 (0.190–1.582)

0.2662

  

0.523 (0.217–1.258)

0.1478

  

SF3B1 WT VS MUT

2.156 (0.514–9.036)

0.2934

  

1.781 (0.547–5.797)

0.3377

  

SRSF2 WT VS MUT

0.701 (0.287–1.712)

0.4352

  

0.514 (0.235–1.122)

0.0948

  

TET2 WT VS MUT

2.861 (1–8.188)

0.05

3.573 (1.185–10.773)

0.0237

1.793 (0.749–4.293)

0.19

  

TP53 WT VS MUT

0.38 (0.173–0.833)

0.0157

0.225 (0.094–0.537)

0.0008

0.463 (0.217–0.988)

0.0463

0.255 (0.111–0.585)

0.0013

U2AF1 WT VS MUT

0.392 (0.15–1.026)

0.0563

  

0.628 (0.245–1.614)

0.3342

  

ZRSF2 WT VS MUT

0.351 (0.138–0.893)

0.0279

  

0.426 (0.191–0.949)

0.0369

  
  1. Mutations present in less than four patients were excluded from the analysis